Stryker Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Stryker wird ein jährliches Gewinn- und Umsatzwachstum von 16.4% bzw. 8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 16.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 21.8% betragen.
Wichtige Informationen
16.4%
Wachstumsrate der Gewinne
16.13%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 16.4% |
| Wachstumsrate der Einnahmen | 8.0% |
| Zukünftige Eigenkapitalrendite | 21.81% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 12 Jun 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Seeking Alpha • Jul 02
Stryker: The Reshaped Product Portfolio Will Drive Growth
Summary Stryker is a Dividend Aristocrat with 32 years of increases, robust cash flow, and a strong M&A-driven growth strategy. SYK's Q1 2026 results were impacted by a cybersecurity incident, but management maintained full-year guidance and expects normalization. The stock trades at ~21x 2026E EPS, below its 5-year average, suggesting undervaluation despite recent share price declines. I rate SYK a 'buy' due to its resilient business model, conservative payout, and platform-based portfolio diversification. Read the full article on Seeking Alpha
Narrativ-Update • Jun 14
SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Recovery Prospects
Stryker's fair value estimate has been adjusted slightly lower to $386.80 from $389.24 as analysts temper price targets in response to lower utilization expectations, inflation headwinds, and more conservative long term margin and P/E assumptions. Analyst Commentary Recent Street research on Stryker has been active, with most updates focused on resetting price targets and reassessing long term assumptions around utilization, inflation, and margins.Narrativ-Update • May 31
SYK: Hospital Digitization And Cyber Resilience Will Drive 2026 Rebound Potential
Analysts have trimmed Stryker's updated price target slightly, reflecting a minor change of about $0.11 and combining a series of recent target cuts from multiple firms with one modest increase, as they reassess assumptions around discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts who recently raised or affirmed higher targets highlight what they see as healthy fundamentals in U.S. medical technology, which they argue can support Stryker's growth assumptions that underpin current P/E expectations.Narrativ-Update • May 14
SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Upside
Analysts have nudged Stryker's fair value estimate lower to about $389 from roughly $419, as a wave of reduced price targets led by firms like Truist, Barclays and others has been paired with updated assumptions for slightly lower future P/E multiples, alongside higher projected revenue growth and profit margins. Analyst Commentary Recent research around Stryker has tilted more cautious, with a cluster of reduced price targets across multiple firms, offset by a smaller group of more supportive views.Analyseartikel • May 04
Stryker Corporation Just Missed Earnings - But Analysts Have Updated Their Models
As you might know, Stryker Corporation ( NYSE:SYK ) last week released its latest first-quarter, and things did not...Narrativ-Update • Apr 21
SYK: Diversified Portfolio And Hospital Digitization Will Support 2026 Upside
Analysts have trimmed Stryker's fair value estimate by about $6 to $419, reflecting slightly higher discount rate assumptions, a modestly lower revenue growth outlook, and a slightly lower future P/E multiple, even as profit margin expectations are marginally higher. Analyst Commentary Recent Street research on Stryker shows a mix of optimism about the company’s long term growth drivers and caution around near term valuation and risk.Narrativ-Update • Apr 06
SYK: Diversified Growth Drivers And Robotics Adoption Will Support 2026 Upside
The updated analyst price target for Stryker edges slightly higher to about $425 per share, as analysts balance recent target trims with continued support from firms highlighting a healthy U.S. medtech backdrop, diversified growth drivers, and potential near term catalysts. Analyst Commentary Recent research paints a mixed but generally constructive picture for Stryker, with several firms adjusting price targets and ratings as they reassess growth drivers, execution, and valuation against a still supportive U.S. medtech backdrop.Narrativ-Update • Mar 22
SYK: Diversified Portfolio And Robotics Adoption Will Support 2026 Upside
Analysts have trimmed the Stryker fair value estimate by less than $1 to about $424 per share, reflecting a slightly higher discount rate and a modestly lower assumed future P/E multiple. Recent research cites mixed price target moves and differing views on near term catalysts and sector trends.Narrativ-Update • Mar 07
SYK: Diversified Product Reach And Robotics Expansion Will Support 2026 Upside
The analyst fair value estimate for Stryker has edged up by about $0.50 to $424.90, as analysts factor in recent price target moves, including several Outperform ratings that highlight the company's broader product reach and diversified growth profile. Analyst Commentary Recent research on Stryker reflects a mix of optimism about the company’s growth profile and some caution on valuation and sector level risks.Narrativ-Update • Feb 20
SYK: Diversified Medtech Portfolio And Robotics Execution Will Support 2026 Upside
Analysts made a modest trim to their blended Stryker price target, reflecting mixed recent revisions that range from higher targets up to $465 with Outperform ratings to lower targets near $390 and $399 with a Hold rating, as they weigh the company's broader product reach and expected sales and earnings trends against valuation and sector-level risks. Analyst Commentary Recent research on Stryker reflects a split view, with some analysts leaning into the growth story and others more guarded on valuation and sector risks.Analyseartikel • Feb 09
Stryker's (NYSE:SYK) Earnings Seem To Be Promising
Stryker Corporation's ( NYSE:SYK ) recent earnings report didn't offer any surprises, with the shares unchanged over...Analyseartikel • Feb 07
Stryker (NYSE:SYK) Is Due To Pay A Dividend Of $0.88
Stryker Corporation ( NYSE:SYK ) will pay a dividend of $0.88 on the 30th of April. This takes the annual payment to...Narrativ-Update • Feb 06
SYK: Orthopedics And Robotics Execution Will Support 2026 Rebound In Medtech Sentiment
Analysts have reduced their fair value estimate for Stryker by about $3 to $424, reflecting slightly softer revenue growth assumptions, a future P/E multiple closer to 34, and a modestly higher profit margin outlook following recent mixed price target changes across Wall Street. Analyst Commentary Recent research coverage on Stryker reflects a mix of optimism and caution, with several firms adjusting price targets and ratings in different directions.Narrativ-Update • Jan 22
SYK: Orthopedics And Robotics Execution Will Support 2026 Upside Potential
Analysts have inched their average price target on Stryker higher, with a modest fair value lift to about US$427.40, as they weigh mixed target changes across firms against ongoing views that the company remains a high quality large-cap MedTech name heading into 2026. Analyst Commentary Recent Street research on Stryker shows a split tape, with several firms lifting targets and ratings while others trim fair values or stay neutral.Narrativ-Update • Jan 08
SYK: Orthopedics Strength And Robotics Adoption Will Support Long-Term Upside
Narrative Update: Stryker The analyst price target for Stryker has been adjusted slightly lower to reflect a fair value estimate of about $427.22. Analysts point to mixed but generally solid recent research that highlights compressed forward multiples, updated targets in the $390 to $453 range, and ongoing views of Stryker as a high quality large cap MedTech name, with attractive entry points and healthy procedure and CapEx trends into 2026.Narrativ-Update • Dec 19
SYK: Expanding Orthopedics And Robotics Footprint Will Drive Long-Term Upside Potential
Analysts have modestly trimmed our fair value estimate for Stryker to approximately $428 from about $433 per share, reflecting a slightly higher discount rate and lower valuation multiple, even as they acknowledge improving revenue growth, rising profit margins, and continued operating leverage highlighted in recent research updates and investor day commentary. Analyst Commentary Street research on Stryker has been active in recent weeks, with modestly higher and lower price targets reflecting a balanced mix of optimism on execution and caution on MedTech sentiment and relative growth.Analyseartikel • Dec 14
Stryker (NYSE:SYK) Has Announced That It Will Be Increasing Its Dividend To $0.88
Stryker Corporation's ( NYSE:SYK ) periodic dividend will be increasing on the 30th of January to $0.88, with investors...Analyseartikel • Sep 08
Does Stryker (NYSE:SYK) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Aug 08
Investors Can Find Comfort In Stryker's (NYSE:SYK) Earnings Quality
NYSE:SYK 1 Year Share Price vs Fair Value Explore Stryker's Fair Values from the Community and select yours The most...Analyseartikel • Jul 09
Estimating The Intrinsic Value Of Stryker Corporation (NYSE:SYK)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Stryker fair value estimate is US$371 With US$390 share price...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 31,970 | 6,493 | 5,714 | 7,837 | 20 |
| 12/31/2027 | 29,582 | 5,544 | 4,911 | 6,753 | 26 |
| 12/31/2026 | 27,267 | 4,845 | 3,668 | 5,016 | 26 |
| 3/31/2026 | 25,270 | 3,337 | 4,571 | 5,375 | N/A |
| 12/31/2025 | 25,116 | 3,246 | 4,283 | 5,044 | N/A |
| 9/30/2025 | 24,381 | 2,943 | 4,073 | 4,832 | N/A |
| 6/30/2025 | 23,818 | 2,918 | 4,024 | 4,766 | N/A |
| 3/31/2025 | 23,218 | 2,859 | 3,577 | 4,288 | N/A |
| 12/31/2024 | 22,595 | 2,993 | 3,487 | 4,242 | N/A |
| 9/30/2024 | 21,974 | 3,590 | 3,205 | 3,839 | N/A |
| 6/30/2024 | 21,389 | 3,448 | 2,803 | 3,415 | N/A |
| 3/31/2024 | 20,963 | 3,361 | 2,858 | 3,470 | N/A |
| 12/31/2023 | 20,498 | 3,165 | 3,136 | 3,711 | N/A |
| 9/30/2023 | 19,885 | 2,585 | 2,568 | 3,186 | N/A |
| 6/30/2023 | 19,455 | 2,709 | 2,417 | 3,025 | N/A |
| 3/31/2023 | 18,952 | 2,627 | 2,267 | 2,866 | N/A |
| 12/31/2022 | 18,449 | 2,358 | 2,036 | 2,624 | N/A |
| 9/30/2022 | 17,948 | 2,457 | 2,015 | 2,621 | N/A |
| 6/30/2022 | 17,629 | 2,079 | 2,067 | 2,665 | N/A |
| 3/31/2022 | 17,430 | 2,015 | 2,453 | 3,014 | N/A |
| 12/31/2021 | 17,108 | 1,994 | 2,738 | 3,263 | N/A |
| 9/30/2021 | 16,669 | 1,900 | 3,016 | 3,500 | N/A |
| 6/30/2021 | 16,246 | 2,083 | 2,973 | 3,396 | N/A |
| 3/31/2021 | 14,716 | 1,408 | 2,712 | 3,138 | N/A |
| 12/31/2020 | 14,351 | 1,599 | 2,790 | 3,277 | N/A |
| 9/30/2020 | 14,220 | 1,756 | 2,254 | 2,775 | N/A |
| 6/30/2020 | 14,070 | 1,601 | 1,960 | 2,575 | N/A |
| 3/31/2020 | 14,956 | 2,164 | 1,798 | 2,469 | N/A |
| 12/31/2019 | 14,884 | 2,083 | N/A | 2,191 | N/A |
| 9/30/2019 | 14,549 | 3,426 | N/A | 2,502 | N/A |
| 6/30/2019 | 14,204 | 3,550 | N/A | 2,491 | N/A |
| 3/31/2019 | 13,876 | 3,522 | N/A | 2,626 | N/A |
| 12/31/2018 | 13,601 | 3,553 | N/A | 2,610 | N/A |
| 9/30/2018 | 13,276 | 1,236 | N/A | 2,243 | N/A |
| 6/30/2018 | 13,040 | 1,080 | N/A | 1,704 | N/A |
| 3/31/2018 | 12,730 | 1,019 | N/A | 1,705 | N/A |
| 12/31/2017 | 12,444 | 1,020 | N/A | 1,559 | N/A |
| 9/30/2017 | 12,130 | 1,779 | N/A | 1,538 | N/A |
| 6/30/2017 | 11,957 | 1,700 | N/A | 1,961 | N/A |
| 3/31/2017 | 11,785 | 1,689 | N/A | 1,804 | N/A |
| 12/31/2016 | 11,325 | 1,647 | N/A | 1,915 | N/A |
| 9/30/2016 | 10,883 | 1,659 | N/A | 1,928 | N/A |
| 6/30/2016 | 10,470 | 1,605 | N/A | 917 | N/A |
| 3/31/2016 | 10,062 | 1,617 | N/A | 781 | N/A |
| 12/31/2015 | 9,946 | 1,439 | N/A | 981 | N/A |
| 9/30/2015 | 9,849 | 1,177 | N/A | 907 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: SYKDas prognostizierte Gewinnwachstum (16.4% pro Jahr) liegt über der Sparquote (3.5%).
Ertrag vs. Markt: SYKDie Erträge des Unternehmens (16.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (18.4% pro Jahr).
Hohe Wachstumserträge: SYKDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: SYKDie Einnahmen des Unternehmens (8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (12.7% pro Jahr).
Hohe Wachstumseinnahmen: SYKDie Einnahmen des Unternehmens (8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: SYKDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (21.8%)
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/05 02:53 |
| Aktienkurs zum Tagesende | 2026/07/02 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Stryker Corporation wird von 53 Analysten beobachtet. 26 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Toung | Argus Research Company |
| Jeffrey Johnson | Baird |
| Matthew Miksic | Barclays |